siderosis lung treatment

Treatment for Lung Siderosis

Many people with siderosis in the lungs don’t require treatment initially. In fact, siderosis alone does not produce noticeable symptoms. The problem with this condition is its tendency to give rise to other, more serious chronic lung diseases, such as chronic obstructive pulmonary disease (COPD) and emphysema. These diseases cause disruptive symptoms like shortness of breath and persistent coughing, which can grow worse over time and substantially impact an individual’s quality of life. Traditional treatment methods for lung siderosis-related conditions are not curative and focus only on reducing symptoms, and can include corticosteroids, supplemental oxygen and breathing exercises.

The Lung Institute offers a breakthrough in chronic lung disease treatment for patients who cannot find satisfactory symptom relief through traditional therapies alone. We specialize in cellular therapy – a natural, minimally invasive treatment that is performed on an outpatient basis over the course of two days. During this therapy, the patient’s own cells are harvested through either a blood draw or through a bone marrow procedure, processed in an onsite clinical lab and returned to the patient intravenously. Cellular treatment has been shown to reduce lung inflammation and the severity of symptoms in certain cases. In fact, more than 80 percent of patients who receive treatment at the Lung Institute report an improvement in overall quality of life.

While there is not yet a curative treatment for siderosis and related lung diseases, there may be a way to improve your quality of life if you have been diagnosed with one of these chronic conditions. Allow the Lung Institute team to help you explore your alternative treatment options. By contacting a member of our devoted team at 888-745-6697, you’ll be able to learn if you are a candidate for cellular therapy.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.